Sage ERP X3, part of the Sage Group plc and Netvibes Limited announced a strategic sales, marketing and technology alliance to develop and distribute new solutions to simplify everyday business processes and personalize the workforce environment. These new technologies will be presented in first quarter 2010, as part of the next generation of Sage ERP X3. Effective immediately, this strategic partnership aligns the two companies' sales, marketing and technology efforts to rapidly bring new Enterprise 2.0 innovations to mid-market companies worldwide. Joint development has already begun on new personal workspace dashboard technologies that will bridge the gap between professional enterprise tools and personal Web 2.0 applications and content, enabling the workforce to seamlessly manage both on a personal, individual level from any web capable device. These new features will be presented in first quarter of 2010, as an integral part of the much anticipated launch of the next generation Sage ERP X3, which will help mid-sized enterprises simplify processes, streamline expenses and personalize interfaces for individual workers. Sage ERP X3 also joins as a premier reseller partner of Netvibes personal dashboard publishing solutions. With this new partnership, Netvibes personal dashboard publishing technology will further expand to reach the businesses that rely on Sage ERP X3 in more than 39 countries.

Sage Group plc reported that net debt fell to £491 million ($810 million) at the end of June 2009 from £558 million at the end of March. The group expects results for the fiscal year to be in line with market forecasts. Sage said most of its regions continue to be resilient, while North America is making good progress in its restructuring and it remains confident the region can achieve medium-term margin goals.

Sage Group plc announced that HemispherX Biopharma has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental immunotherapeutic) for Chronic Fatigue Syndrome, additional partnering efforts related to Ampligen's use to increase the effectiveness of preventative pandemic flu vaccines and the additional role of Alferon LDO (an experimental therapeutic) for treating various types of pandemic flu. In particular, Sage is assisting HemispherX in its work with the Japanese government in the rapid development of a response strategy for pandemic flu.